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Recently, a single center study conducted by Oiva and 
coworkers and published in Critical Care [1] demon-
strated that phospho-speciﬁ   c whole blood ﬂ  ow  cyto-
metry could be used to assess activated signaling path-
ways in leukocytes isolated from pancreatitis patients. 
Pancreatitis is an inﬂ  ammatory process in which pan-
creatic enzymes are activated leading to autodigestion of 
the pancreas and adjacent tissues. During pernicious 
cases, the initial inﬂ  ammatory response is excessive and 
can result in tissue injury, organ failure, and death. To 
counter this inﬂ  ammation, the immune system initiates a 
number of inﬂ  ammatory terminating steps. Th  ese steps 
can include leukocyte apoptosis, anti-inﬂ  ammatory 
cytokine production, and anergy [2,3]. When patients 
become leukopenic and immunosuppressed, they often 
become susceptible to infections with organisms to 
which a healthy patient would normally be resistant. 
Although therapy aimed at blunting the initial over-
exuberant inﬂ   ammation may be beneﬁ   cial if applied 
early, it may also be detrimental by impairing the host’s 
ability to ﬁ  ght infection that is a common cause of death 
in these patients. To complicate the potential use of 
immune-modulating therapy, inﬂ   ammatory and anti-
inﬂ  ammatory processes can occur along diﬀ  erent time-
lines for the varied leukocyte subsets. For example, during 
immune response, T lymphocytes might be under  going 
apoptosis while neutrophils are primed to produce reactive 
oxygen species [4]. Th  us, during pro  longed pancreatitis, 
leukocyte subsets may be concur  rently exhibiting both 
pro- and anti-inﬂ  ammatory processes.
As noted above, a potential promising therapy of 
pancreatitis is modulation of the immune response [5]. 
Th   is is a diﬃ   cult undertaking as the host response will be 
aﬀ   ected by a number of variables, including genetic 
background, co-morbidities, age, gender, and so on [6]. In 
addition, the patient’s immune response will vary during 
the course of the disease. Th  us, what is needed for 
immunotherapy to be practical is a rapid, robust measure 
of the host immune system.
In the manuscript published by Oiva and co-workers 
[1], the authors determined the signaling proﬁ  les  of 
circulating leukocytes isolated from pancreatitis patients 
using phospho-speciﬁ  c whole blood ﬂ  ow cytometry. Th  is 
is a powerful new technology that allows for simultaneous 
single-cell determination of leukocyte subsets using cell 
surface markers as well as intracellular protein phos-
phory  lation [7]. Th  is work represents a continuation of 
work published previously [8]. In this earlier work, Oiva 
and co-workers demonstrated that stimulated monocytes 
isolated from patients with acute pancreatitis had 
decreased phosphorylated Erk 1/2, NF-κB, and STAT1 
and 3. Th  e authors concluded that these changes could 
lead to impaired monocyte recruitment as well as 
increased susceptibility to infections. Here, changes in 
activated T lymphocyte p38, NF-κB, STAT1 and STAT6 
activity was observed that could be interpreted as being 
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that patients’ lymphocytes exhibited decreased phos-
phory  lated NF-κB and STAT1 and increased phos-
phorylation of p38 and STAT6, suggesting a transition 
from a Th  1 to Th  2 phenotype. Additionally, this mini-
mally invasive methodology could be used to generate 
immune status within 6 hours under ideal conditions. 
Th   us, this methodology represents an essential step prior 
to targeting the underlying immune response to 
pancreatitis.
Although beyond the scope of the report, a potentially 
necessary step after immune status determination, and 
prior to treatment with inﬂ  ammatory altering treatments, 
would be to ﬁ  rst treat the whole blood cells isolated from 
the patients with the potential therapeutic agent and 
evaluate the immune eﬀ   ector cell response. Phospho-
speciﬁ  c ﬂ  ow cytometry could also be used to determine if 
the leukocytes responded in a way that would be 
beneﬁ  cial. Th  us, the minimally invasive, relatively quick 
methodology developed in this paper could be utilized to 
determine immune status as well as provide a method to 
test potential therapies.
One unavoidable limitation to the report is that the 
signaling processes were determined using only peri-
pheral leukocytes. A possibility exists that peripheral 
leukocytes may not respond similarly to ex vivo stimuli as 
leukocytes isolated from the inﬂ  ammatory site(s). When 
feasible, future studies need to be undertaken to compare 
the response of peripheral leukocytes to these tissue 
leukocytes.
Rapid results from whole blood phospho-speciﬁ  c ﬂ  ow 
cytometry during pancreatitis will allow for immune 
status determination, likely improve early diagnosis and 
provide a rational basis for immune targeting therapies. 
Altogether, this may signiﬁ  cantly inﬂ  uence the morbidity 
and mortality of these patients.
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